Skip to main content
OpenTrials
Completed

NCT Number: NCT03331276

Growth and Safety Study of an Infant Formula for Healthy Term Infants

A goal of infant formula development is to mimic human milk (HM) both in nutrient composition as well as physiologic outcomes. investigators have developed an infant formula for term infants that more closely resembles the composition of human milk. The purpose of this study is to demonstrate that this formulation meets nutritional requirements and supports age appropriate growth of healthy term infants.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Age range

1 day–14 day

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Alabama Clinical Therapeutics, Birmingham, Alabama, United States

Loading trial locations.

About this study

This study is a randomized, controlled, double-blind, study of healthy term formula fed (FF) infants. FF infants will be randomized to receive either a experimental infant formula, formulated for healthy term infants (BBN) or a commercially available infant formula for healthy term infants (Brand). Infants will consume the formula for a total of 16-weeks; infant growth, serum markers for inflammation and tolerance to the formulas will be assessed throughout the study.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Infants will be eligible to participate if they meet all of the following conditions. At birth the infant must be:
  • Healthy, term (early term/no less than 37 weeks, 0 days through late term/no greater than 41 weeks, 6 days), singleton infant
  • Have a birth weight of ≥ 2500 grams

At the time of the baseline/enrollment visit, infants must be:

  • Designated as healthy by a physician
  • ≤14 days post-natal age (Date of Birth = Day 0)
  • Weight for age ≥ 5th and ≤ 95th percentile for age according to sex-specific World Health Organization (WHO) growth charts
  • Length for age ≥ 5th and ≤ 95th percentile for age according to sex-specific World Health Organization (WHO) growth charts
  • Head circumference for age ≥ 5th and ≤ 95th percentile for age according to sex-specific World Health Organization (WHO) growth charts
  • Weight for length for age ≥ 5th and ≤ 95th percentile for age according to sex-specific World Health Organization (WHO) growth charts
  • Exclusively consuming and tolerating a cow's milk infant formula at time of enrollment; only infants whose parent(s) or legal guardian(s) have decided to feed infant formula as the sole soure of nutrition, will be approached for potential study enrollment
  • Have parent(s) or legal guardian(s) who agree to feed the study formula to the study subject as his/her sole source of nutrition for the duration of the study
  • Have parent(s) or legal guardian(s) who have read and voluntarily signed an Informed Consent form approved by the Institutional Review Board prior to any participation in the study.

Exclusion criteria

Infants will be ineligible if they have any of the following conditions that are judged by a physician to interfere with the infant's normal growth, development, and/or tolerance to an infant formula:

  • Show evidence of anatomic and physiologic defects of the respiratory tract, or other congenital defects (as determined by the clinician);
  • Show evidence of chronic hepatic, gastrointestinal, renal, cardiac, pulmonary, or neurological diseases;
  • Have a maternal history with known adverse effects on the fetus and/or the newborn infant, such as diabetes (gestational diabetes is acceptable if infant's birth weight is < 4300 g), active tuberculosis, perinatal infection, or substance abuse
  • Have a family history of cow's milk protein intolerance/allergy
  • Are an infant from a multiple birth (twin, triplet, etc.) -

Treatment and study plan

BBN

Other

BBN to be feed as the sole source of nutrition for 16 weeks to healthy term infants for 16 weeks.

Other names: BBN-001

Brand

Other

Brand to be feed as the sole source of nutrition for 16 weeks to healthy term infants for 16 weeks.

Other names: Enfamil

Primary outcomes

  1. Weight gain

    Time frame: 16 weeks

    g/d

Secondary outcomes

  1. Mean stool consistency

    Time frame: Monthly for 16 weeks

    1= watery, 2= runny / soft, 3= musy / soft, 4= formed soft, 5= hard

  2. Mean fussiness score

    Time frame: Monthly 16 weeks

    0= less fussy than normal, 1= about the same level of fussiness as normal, 2= more fussy than normal

  3. Mean gassiness score

    Time frame: Monthly 16 weeks

    0= no gas, 1= slight amount of gas, 2= moderate amout of gas, 3= excessive amount of gas

  4. Mean interleukin - 6 Concentration

    Time frame: at 16 weeks

    IL - 6 ng/ml

  5. Mean interleukin - 10 Concentration

    Time frame: at 16 weeks

    IL - 10 pg/ml

  6. Mean tumor necrosis factor alpha Concentration

    Time frame: at 16 weeks

    TNF - alpha pg/ml

Sponsors and collaborators

Lead sponsor

Building Block Nutritionals, LLC

Industry

Collaborators

  • Paidion Research, Inc.

Registry information

Important dates

Study start
2017
Primary completion
2019
Study completion
2019
First posted
Nov 6, 2017
Registry last updated
Oct 19, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.